Summary

The global PARG Inhibitor market is projected to grow from US$ 0.30 million in 2025 to US$ 1.60 million by 2032, at a CAGR of 21.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
A PARG inhibitor blocks poly(ADP-ribose) glycohydrolase, which removes poly(ADP-ribose) chains during cellular DNA-damage responses. Preventing this turnover can disrupt replication-fork recovery and increase replication stress in susceptible tumour cells. Unlike PARP inhibition, it acts on polymer degradation rather than synthesis. Development requires selective engagement, sufficient intracellular exposure, pharmacodynamic evidence and a therapeutic window between tumour and normal proliferating tissue. Clinical value depends on tolerable, durable activity in defined populations, not an assumption that all PARP-resistant cancers respond.
Key Findings
PARG inhibition targets polymer removal within DNA damage response pathways
Clinical development separates monotherapy testing from emerging combination strategies
Biomarker selection must be validated rather than borrowed from PARP
Market Trends
PARG development is moving from target rationale into human dose selection and combination testing. IDE161 is being evaluated with a TOP1-payload ADC, and ETX-19477 has a first-in-human programme. DAT-2645, SYN608 and QLS1403 provide distinct Chinese development routes. Exposure, pharmacodynamics and reproducible cohort activity increasingly determine progress, with different evidence levels requiring separate interpretation.
Market Dynamics
Drivers
Impaired fork protection or high replication stress creates a rationale for disrupting PARG-mediated turnover. Unmet needs after existing DNA-repair therapies support clinical investment. Current direct demand is for controlled evaluation and translational assays rather than routine hospital drug purchasing.
Restraints
PARG also participates in normal DNA responses, so an adequate therapeutic window is not guaranteed. Early cohorts provide incomplete information on durability and uncommon toxicity. Without an approved label and pricing evidence, revenue projections remain less grounded than development milestones.
Opportunities
TOP1-payload combinations can test whether impaired repair of payload-induced lesions adds antitumour activity. Overlapping toxicity requires an independently evaluated schedule. Molecularly selected ovarian and breast cancer studies offer another route, but PARP resistance alone is not a validated universal selection rule.
Challenges
Preclinical biomarker signals may not predict benefit across heterogeneous human tumours. Prospective sampling, consistent assays and follow-up are needed to separate activity from cohort-selection effects. Funding continuity and feasible comparative trials determine whether dose-escalation findings can reach registration.
Industry Chain Analysis
Enzyme assays, chemistry and replication-stress models initiate PARG programmes. Synthesis and formulation teams produce clinical material; sponsors, hospitals and laboratories coordinate escalation, exposure analysis and pharmacodynamic sampling. Value currently resides in intellectual property and human proof of concept. Licensing and research contracts are not finished-drug sales. A commercial chain additionally requires registration, reproducible GMP scale-up, distribution and a payable treatment pathway.
Segment Insights
IDE161 combines dose optimization with clinical combination work, making schedule and pharmacodynamic compatibility central. ETX-19477 has first-in-human development and company updates on initial patient data; these do not establish comparative superiority. DAT-2645 provides a Chinese clinical route. SYN608 has documented clinical authorization, but patient outcomes must not be inferred from permission to start a trial. QLS1403 has company-disclosed preclinical evidence and is classified at that verified level here. The residual molecule category accommodates later assets without turning undisclosed compounds or reagent catalogues into established therapeutic competitors.
Downstream Market Opportunities
Ovarian studies must record platinum resistance, molecular criteria and prior therapy. Breast cohorts need separate interpretation by hormone receptors, BRCA status and treatment history. Endometrial combinations must show PARG contribution beyond the partner. Small-cell lung cancer TOP1-payload combinations address a different context and cannot inherit ovarian response assumptions. Other tumour cohorts remain exploratory until activity and a registration strategy are established.
Regional Insights
The United States hosts important IDE161 and ETX-19477 programmes. China contributes original development through Danatlas, SynRx and Qilu, with Chinese trials and US authorization appearing in different projects. These describe research geography, not drug-sales shares. Tissue access, trial capacity and previous treatment affect cross-region data transferability. European and Japanese participation may develop later, but current evidence does not justify assigning commercial totals to those regions.
Competitive Landscape Analysis
Representative companies include IDEAYA Biosciences, 858 Therapeutics, Danatlas Pharmaceuticals, SynRx Therapeutics and Qilu Pharmaceutical. IDEAYA advances IDE161 combinations; 858 develops ETX-19477 in humans; Danatlas progresses DAT-2645 clinically; SynRx has disclosed SYN608 authorization; Qilu has presented QLS1403 preclinical work. Competition centres on validated selection, exposure and safety and a credible registration route. Different stages and cohorts cannot produce a direct efficacy ranking or an approved manufacturing position.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global PARG Inhibitor market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
IDEAYA Biosciences
858 Therapeutics
Danatlas Pharmaceuticals
SynRx Therapeutics
Qilu Pharmaceutical
Segment by Type
IDE161
ETX-19477
DAT-2645
SYN608
QLS1403
Others
Segment by Biomarker Strategy
BRCA1/2 Mutation-selected
Others
Segment by Application
Ovarian Cancer
Breast Cancer
Endometrial Cancer
Small-cell Lung Cancer
Others
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the PARG Inhibitor study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to PARG Inhibitor: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global PARG Inhibitor Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 IDE161
1.2.3 ETX-19477
1.2.4 DAT-2645
1.2.5 SYN608
1.2.6 QLS1403
1.2.7 Others
1.3 Market Segmentation by Biomarker Strategy
1.3.1 Global PARG Inhibitor Market Size by Biomarker Strategy, 2021 vs 2025 vs 2032
1.3.2 BRCA1/2 Mutation-selected
1.3.3 Others
1.4 Market Segmentation by Application
1.4.1 Global PARG Inhibitor Market Size by Application, 2021 vs 2025 vs 2032
1.4.2 Ovarian Cancer
1.4.3 Breast Cancer
1.4.4 Endometrial Cancer
1.4.5 Small-cell Lung Cancer
1.4.6 Others
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global PARG Inhibitor Revenue Estimates and Forecasts (2021-2032)
2.2 Global PARG Inhibitor Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global PARG Inhibitor Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global PARG Inhibitor Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 IDE161: Market Share by Key Players
3.3.2 ETX-19477: Market Share by Key Players
3.3.3 DAT-2645: Market Share by Key Players
3.3.4 SYN608: Market Share by Key Players
3.3.5 QLS1403: Market Share by Key Players
3.3.6 Others: Market Share by Key Players
3.4 Global PARG Inhibitor Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global PARG Inhibitor Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global PARG Inhibitor Market by Biomarker Strategy
4.2.1 Global Revenue by Biomarker Strategy (2021-2032)
4.2.2 Global Revenue-Based Market Share by Biomarker Strategy (2021-2032)
4.3 Key Product Attributes and Differentiation
4.4 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.4.1 High-Growth Niches and Adoption Drivers
4.4.2 Profitability Hotspots and Cost Drivers
4.4.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global PARG Inhibitor Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America PARG Inhibitor Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America PARG Inhibitor Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe PARG Inhibitor Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe PARG Inhibitor Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific PARG Inhibitor Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific PARG Inhibitor Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America PARG Inhibitor Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America PARG Inhibitor Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa PARG Inhibitor Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa PARG Inhibitor Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 IDEAYA Biosciences
11.1.1 IDEAYA Biosciences Corporation Information
11.1.2 IDEAYA Biosciences Business Overview
11.1.3 IDEAYA Biosciences PARG Inhibitor Product Features and Attributes
11.1.4 IDEAYA Biosciences PARG Inhibitor Revenue and Gross Margin (2021-2026)
11.1.5 IDEAYA Biosciences PARG Inhibitor Revenue by Product in 2025
11.1.6 IDEAYA Biosciences PARG Inhibitor Revenue by Application in 2025
11.1.7 IDEAYA Biosciences PARG Inhibitor Revenue by Geographic Area in 2025
11.1.8 IDEAYA Biosciences PARG Inhibitor SWOT Analysis
11.1.9 IDEAYA Biosciences Recent Developments
11.2 858 Therapeutics
11.2.1 858 Therapeutics Corporation Information
11.2.2 858 Therapeutics Business Overview
11.2.3 858 Therapeutics PARG Inhibitor Product Features and Attributes
11.2.4 858 Therapeutics PARG Inhibitor Revenue and Gross Margin (2021-2026)
11.2.5 858 Therapeutics PARG Inhibitor Revenue by Product in 2025
11.2.6 858 Therapeutics PARG Inhibitor Revenue by Application in 2025
11.2.7 858 Therapeutics PARG Inhibitor Revenue by Geographic Area in 2025
11.2.8 858 Therapeutics PARG Inhibitor SWOT Analysis
11.2.9 858 Therapeutics Recent Developments
11.3 Danatlas Pharmaceuticals
11.3.1 Danatlas Pharmaceuticals Corporation Information
11.3.2 Danatlas Pharmaceuticals Business Overview
11.3.3 Danatlas Pharmaceuticals PARG Inhibitor Product Features and Attributes
11.3.4 Danatlas Pharmaceuticals PARG Inhibitor Revenue and Gross Margin (2021-2026)
11.3.5 Danatlas Pharmaceuticals PARG Inhibitor Revenue by Product in 2025
11.3.6 Danatlas Pharmaceuticals PARG Inhibitor Revenue by Application in 2025
11.3.7 Danatlas Pharmaceuticals PARG Inhibitor Revenue by Geographic Area in 2025
11.3.8 Danatlas Pharmaceuticals PARG Inhibitor SWOT Analysis
11.3.9 Danatlas Pharmaceuticals Recent Developments
11.4 SynRx Therapeutics
11.4.1 SynRx Therapeutics Corporation Information
11.4.2 SynRx Therapeutics Business Overview
11.4.3 SynRx Therapeutics PARG Inhibitor Product Features and Attributes
11.4.4 SynRx Therapeutics PARG Inhibitor Revenue and Gross Margin (2021-2026)
11.4.5 SynRx Therapeutics PARG Inhibitor Revenue by Product in 2025
11.4.6 SynRx Therapeutics PARG Inhibitor Revenue by Application in 2025
11.4.7 SynRx Therapeutics PARG Inhibitor Revenue by Geographic Area in 2025
11.4.8 SynRx Therapeutics PARG Inhibitor SWOT Analysis
11.4.9 SynRx Therapeutics Recent Developments
11.5 Qilu Pharmaceutical
11.5.1 Qilu Pharmaceutical Corporation Information
11.5.2 Qilu Pharmaceutical Business Overview
11.5.3 Qilu Pharmaceutical PARG Inhibitor Product Features and Attributes
11.5.4 Qilu Pharmaceutical PARG Inhibitor Revenue and Gross Margin (2021-2026)
11.5.5 Qilu Pharmaceutical PARG Inhibitor Revenue by Product in 2025
11.5.6 Qilu Pharmaceutical PARG Inhibitor Revenue by Application in 2025
11.5.7 Qilu Pharmaceutical PARG Inhibitor Revenue by Geographic Area in 2025
11.5.8 Qilu Pharmaceutical PARG Inhibitor SWOT Analysis
11.5.9 Qilu Pharmaceutical Recent Developments

12 PARG Inhibitor Value Chain and Ecosystem Analysis
12.1 PARG Inhibitor Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 PARG Inhibitor Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global PARG Inhibitor Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global PARG Inhibitor Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global PARG Inhibitor Market Size Growth Rate by Biomarker Strategy, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global PARG Inhibitor Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global PARG Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global PARG Inhibitor Revenue by Region (US$ Million), 2021-2026
Table 6. Global PARG Inhibitor Revenue by Region (US$ Million), 2027-2032
Table 7. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 8. Global PARG Inhibitor Revenue by Players (US$ Million), 2021-2026
Table 9. Global PARG Inhibitor Revenue-Based Market Share by Players (2021-2026)
Table 10. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 11. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on PARG Inhibitor Revenue, 2025
Table 12. Global PARG Inhibitor Average Gross Margin (%) by Player (2021 vs 2025)
Table 13. Global PARG Inhibitor Companies Headquarters
Table 14. Global PARG Inhibitor Market Concentration Ratio (CR5)
Table 15. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 16. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 17. Global PARG Inhibitor Revenue by Type (US$ Million), 2021-2026
Table 18. Global PARG Inhibitor Revenue by Type (US$ Million), 2027-2032
Table 19. Global PARG Inhibitor Revenue by Biomarker Strategy (US$ Million), 2021-2026
Table 20. Global PARG Inhibitor Revenue by Biomarker Strategy (US$ Million), 2027-2032
Table 21. Key Product Attributes and Differentiation
Table 22. Global PARG Inhibitor Revenue by Application (US$ Million), 2021-2026
Table 23. Global PARG Inhibitor Revenue by Application (US$ Million), 2027-2032
Table 24. PARG Inhibitor High-Growth Sectors Demand CAGR (2026-2032)
Table 25. Top Customers by Region
Table 26. Top Customers by Application
Table 27. North America PARG Inhibitor Growth Accelerators and Market Barriers
Table 28. North America PARG Inhibitor Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 29. Europe PARG Inhibitor Growth Accelerators and Market Barriers
Table 30. Europe PARG Inhibitor Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Asia-Pacific PARG Inhibitor Growth Accelerators and Market Barriers
Table 32. Asia-Pacific PARG Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Central and South America PARG Inhibitor Investment Opportunities and Key Challenges
Table 34. Central and South America PARG Inhibitor Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 35. Middle East and Africa PARG Inhibitor Investment Opportunities and Key Challenges
Table 36. Middle East and Africa PARG Inhibitor Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 37. IDEAYA Biosciences Corporation Information
Table 38. IDEAYA Biosciences Description and Major Businesses
Table 39. IDEAYA Biosciences Product Features and Attributes
Table 40. IDEAYA Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 41. IDEAYA Biosciences Revenue Proportion by Product in 2025
Table 42. IDEAYA Biosciences Revenue Proportion by Application in 2025
Table 43. IDEAYA Biosciences Revenue Proportion by Geographic Area in 2025
Table 44. IDEAYA Biosciences PARG Inhibitor SWOT Analysis
Table 45. IDEAYA Biosciences Recent Developments
Table 46. 858 Therapeutics Corporation Information
Table 47. 858 Therapeutics Description and Major Businesses
Table 48. 858 Therapeutics Product Features and Attributes
Table 49. 858 Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 50. 858 Therapeutics Revenue Proportion by Product in 2025
Table 51. 858 Therapeutics Revenue Proportion by Application in 2025
Table 52. 858 Therapeutics Revenue Proportion by Geographic Area in 2025
Table 53. 858 Therapeutics PARG Inhibitor SWOT Analysis
Table 54. 858 Therapeutics Recent Developments
Table 55. Danatlas Pharmaceuticals Corporation Information
Table 56. Danatlas Pharmaceuticals Description and Major Businesses
Table 57. Danatlas Pharmaceuticals Product Features and Attributes
Table 58. Danatlas Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 59. Danatlas Pharmaceuticals Revenue Proportion by Product in 2025
Table 60. Danatlas Pharmaceuticals Revenue Proportion by Application in 2025
Table 61. Danatlas Pharmaceuticals Revenue Proportion by Geographic Area in 2025
Table 62. Danatlas Pharmaceuticals PARG Inhibitor SWOT Analysis
Table 63. Danatlas Pharmaceuticals Recent Developments
Table 64. SynRx Therapeutics Corporation Information
Table 65. SynRx Therapeutics Description and Major Businesses
Table 66. SynRx Therapeutics Product Features and Attributes
Table 67. SynRx Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 68. SynRx Therapeutics Revenue Proportion by Product in 2025
Table 69. SynRx Therapeutics Revenue Proportion by Application in 2025
Table 70. SynRx Therapeutics Revenue Proportion by Geographic Area in 2025
Table 71. SynRx Therapeutics PARG Inhibitor SWOT Analysis
Table 72. SynRx Therapeutics Recent Developments
Table 73. Qilu Pharmaceutical Corporation Information
Table 74. Qilu Pharmaceutical Description and Major Businesses
Table 75. Qilu Pharmaceutical Product Features and Attributes
Table 76. Qilu Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 77. Qilu Pharmaceutical Revenue Proportion by Product in 2025
Table 78. Qilu Pharmaceutical Revenue Proportion by Application in 2025
Table 79. Qilu Pharmaceutical Revenue Proportion by Geographic Area in 2025
Table 80. Qilu Pharmaceutical PARG Inhibitor SWOT Analysis
Table 81. Qilu Pharmaceutical Recent Developments
Table 82. Technologies, Platforms and Infrastructure
Table 83. Distributors List
Table 84. Market Trends and Market Evolution
Table 85. Market Drivers and Opportunities
Table 86. Market Challenges, Risks, and Restraints
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources

List of Figures
Figure 1. Global PARG Inhibitor Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. IDE161 Product Picture
Figure 3. ETX-19477 Product Picture
Figure 4. DAT-2645 Product Picture
Figure 5. SYN608 Product Picture
Figure 6. QLS1403 Product Picture
Figure 7. Others Product Picture
Figure 8. Global PARG Inhibitor Market Size Growth Rate by Biomarker Strategy, 2021 vs 2025 vs 2032 (US$ Million)
Figure 9. BRCA1/2 Mutation-selected Product Picture
Figure 10. Others Product Picture
Figure 11. Global PARG Inhibitor Market Size Growth Rate , 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Global PARG Inhibitor Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 13. Ovarian Cancer
Figure 14. Breast Cancer
Figure 15. Endometrial Cancer
Figure 16. Small-cell Lung Cancer
Figure 17. Others
Figure 18. PARG Inhibitor Report Years Considered
Figure 19. Global PARG Inhibitor Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 21. Global PARG Inhibitor Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 22. Global PARG Inhibitor Revenue-Based Market Share by Region (2021-2032)
Figure 23. Global PARG Inhibitor Revenue-Based Market Share Ranking (2025)
Figure 24. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 25. IDE161 Revenue-Based Market Share by Player in 2025
Figure 26. ETX-19477 Revenue-Based Market Share by Player in 2025
Figure 27. DAT-2645 Revenue-Based Market Share by Player in 2025
Figure 28. SYN608 Revenue-Based Market Share by Player in 2025
Figure 29. QLS1403 Revenue-Based Market Share by Player in 2025
Figure 30. Others Revenue-Based Market Share by Player in 2025
Figure 31. Global PARG Inhibitor Revenue-Based Market Share by Type (2021-2032)
Figure 32. Global PARG Inhibitor Revenue-Based Market Share by Biomarker Strategy (2021-2032)
Figure 33. Global PARG Inhibitor Revenue-Based Market Share by Application (2021-2032)
Figure 34. North America PARG Inhibitor Revenue YoY (US$ Million), 2021-2032
Figure 35. North America Top 5 Players PARG Inhibitor Revenue (US$ Million) in 2025
Figure 36. North America PARG Inhibitor Revenue (US$ Million) by Application (2021-2032)
Figure 37. US PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 38. Canada PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 39. Mexico PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 40. Europe PARG Inhibitor Revenue YoY (US$ Million), 2021-2032
Figure 41. Europe Top 5 Players PARG Inhibitor Revenue (US$ Million) in 2025
Figure 42. Europe PARG Inhibitor Revenue (US$ Million) by Application (2021-2032)
Figure 43. Germany PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 44. France PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 45. U.K. PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 46. Italy PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 47. Russia PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 48. Asia-Pacific PARG Inhibitor Revenue YoY (US$ Million), 2021-2032
Figure 49. Asia-Pacific Top 8 Players PARG Inhibitor Revenue (US$ Million) in 2025
Figure 50. Asia-Pacific PARG Inhibitor Revenue (US$ Million) by Application (2021-2032)
Figure 51. Indonesia PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 52. Japan PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 53. South Korea PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 54. Australia PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 55. India PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 56. Indonesia PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 57. Vietnam PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 58. Malaysia PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 59. Philippines PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 60. Singapore PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 61. Central and South America PARG Inhibitor Revenue YoY (US$ Million), 2021-2032
Figure 62. Central and South America Top 5 Players PARG Inhibitor Revenue (US$ Million) in 2025
Figure 63. Central and South America PARG Inhibitor Revenue (US$ Million) by Application (2021-2032)
Figure 64. Brazil PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 65. Argentina PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 66. Middle East and Africa PARG Inhibitor Revenue YoY (US$ Million), 2021-2032
Figure 67. Middle East and Africa Top 5 Players PARG Inhibitor Revenue (US$ Million) in 2025
Figure 68. Middle East and Africa PARG Inhibitor Revenue (US$ Million) by Application (2021-2032)
Figure 69. GCC Countries PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 70. Israel PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 71. Egypt PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 72. South Africa PARG Inhibitor Revenue (US$ Million), 2021-2032
Figure 73. PARG Inhibitor Value Chain Mapping
Figure 74. Channels of Distribution (Direct Vs Distribution)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed